36 results on '"Aumann, Shlomzion"'
Search Results
2. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
3. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis
4. Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
5. Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia.
6. Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
7. Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
8. Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis
9. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
10. P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
11. Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia
12. Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients.
13. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma
14. Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study
15. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
16. IBCL-236 Similar Safety Profile for Rituximab and Obinutuzumab as Maintenance for Follicular Lymphoma: Evidence From a Real-World Multicenter Retrospective Cohort Study
17. Similar Safety Profile for Rituximab and Obinutuzumab as Maintenance for Follicular Lymphoma: Evidence From a Real-World Multicenter Retrospective Cohort Study
18. Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality.
19. Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study.
20. Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
21. Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
22. COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
23. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
24. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
25. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
26. Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature.
27. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
28. LMO2 Facilitates Synthetic Lethality after PARP Inhibition (PARPi) in Diffuse Large B-Cell Lymphoma (DLBCL)
29. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
30. The Utility of a Coagulation Laboratory Profile in Addition to Clinical Risk Factors for Thrombosis Risk Evaluation in Patients with Myeloproliferative Neoplasms: A Pilot Study
31. Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study
32. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
33. Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression
34. Somatic alterations and dysregulation of epigenetic modifiers in cancers
35. Recurrent RASand PIK3CAmutations in Erdheim-Chester disease
36. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease and histiocytic sarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.